{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:22:46Z","timestamp":1762053766398,"version":"build-2065373602"},"reference-count":63,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Samjin Pharmaceutical Co., Ltd. Korea","award":["SJ-IIT-23-11"],"award-info":[{"award-number":["SJ-IIT-23-11"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are the preferred anti-viral agents used as first-line treatments for chronic hepatitis B (CHB). However, the efficacy of these agents in reducing the incidence of hepatocellular carcinoma (HCC) remains unclear. We conducted this meta-analysis to assess the efficacy of anti-viral agent on preventing HCC in CHB. Two investigators independently searched all relevant studies that examined the efficacy of anti-viral agent for preventing HCC using MEDLINE, Embase, and Cochrane Library databases through August 2021. The extracted data were analysed using a random-effects meta-analysis model based on the inverse-variance method (DerSimonian\u2013Laird) and expressed as hazard ratio (HR) and 95% confidence interval (95% CI). We included 19 retrospective studies in the analysis. Although there was substantial heterogeneity between the studies, the overall pooled HR indicated that TDF significantly lowered the risk of HCC (HR: 0.72, 95% CI: 0.58\u20130.90, I2 = 66.29%). However, the pooled analysis of propensity score (PS)-matched subpopulations showed no significant differences (HR, 0.83; 95% CI, 0.65\u20131.06; I2 = 52.30%) between TDF and ETV. In a subgroup analysis, an interval of over three years in the start point of patient enrolment and excluding alcoholic liver disease patients significantly lowered the HCC risk associated with TDF. In conclusion, TDF may be more effective than ETV at reducing HCC incidence in treatment-naive CHB patients, but this effect was not consistent in the PS-matched subpopulation that reduced heterogeneity. As a result of subgroup analysis, the conflicting findings of previous studies may result from heterogeneous inclusion criteria. Further studies with standardised protocols are needed to reduce the residual heterogeneity.<\/jats:p>","DOI":"10.3390\/cancers14112617","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T08:41:33Z","timestamp":1653468093000},"page":"2617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-8808","authenticated-orcid":false,"given":"Hyunwoo","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu 11759, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-3572","authenticated-orcid":false,"given":"Hyo Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu 11759, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-1864","authenticated-orcid":false,"given":"Jihye","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-7773","authenticated-orcid":false,"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, April 18). Hepatitis B. 27 July 2020. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hui, V.W., Chan, S.L., Wong, V.W., Liang, L.Y., Yip, T.C., Lai, J.C., Yuen, B.W., Luk, H.W., Tse, Y.K., and Lee, H.W. (2020). Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Rep., 2.","DOI":"10.1016\/j.jhepr.2020.100152"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1055-9965.EPI-19-0614","article-title":"Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study","volume":"29","author":"Kim","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1136\/gutjnl-2020-321309","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B","volume":"70","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"EASL (2017). 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs. Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.18632\/aging.202573","article-title":"No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs. entecavir: Evidence from an updated meta-analysis","volume":"13","author":"Yuan","year":"2021","journal-title":"Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of Tenofovir vs. Entecavir on Risk of Hepatocellular Carcinoma in Patients with Chronic HBV Infection: A Systematic Review and Meta-analysis","volume":"19","author":"Choi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xia, Z., He, L., Xiong, L., and Wen, T. (2020). The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis. Medicine, 99.","DOI":"10.1097\/MD.0000000000020877"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: A systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","article-title":"Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: A meta-analysis","volume":"69","author":"Teng","year":"2020","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: A critical systematic review and meta-analysis","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis","volume":"35","author":"Gu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cheung, K.S., Mak, L.Y., Liu, S.H., Cheng, H.M., Seto, W.K., Yuen, M.F., and Lai, C.L. (2020). Entecavir vs. Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Clin. Transl. Gastroenterol., 11.","DOI":"10.14309\/ctg.0000000000000236"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhou, Y., Yang, J., Hu, K., and Huang, Y. (2019). The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: A meta analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5735-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/MCG.0000000000001548","article-title":"Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis","volume":"55","author":"Jeong","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1002\/sim.6530","article-title":"Meta-analysis of rate ratios with differential follow-up by treatment arm: Inferring comparative effectiveness of medical devices","volume":"34","author":"Kunz","year":"2015","journal-title":"Stat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","article-title":"Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments","volume":"76","author":"Choi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gordon, S.C., Zhou, Y., Li, J., Rupp, L.B., Boscarino, J.A., Daida, Y.G., Schmidt, M.A., Trudeau, S., and Lu, M. (2019). Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort. J. Hepatol., 70.","DOI":"10.1016\/S0618-8278(19)30259-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs. tenofovir","volume":"25","author":"Kim","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir","volume":"66","author":"Shin","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jfma.2016.08.006","article-title":"Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs","volume":"116","author":"Tsai","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir Is Associated with Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients with Chronic HBV Infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.13194","article-title":"Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir\/tenofovir in South Korea","volume":"48","author":"Yu","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","article-title":"Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir\/tenofovir","volume":"31","author":"Yu","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","article-title":"Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: A retrospective cohort study","volume":"23","author":"Wu","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B","volume":"115","author":"Hsu","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","first-page":"184","article-title":"Long-term clinical outcomes of chronic Hepatitis B patients treated with Entecavir vs. Tenofovir: A retrospective, obseravational, comparative study","volume":"Volume 68","author":"Cho","year":"2018","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jgh.15031","article-title":"Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis","volume":"35","author":"Ha","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No Difference in Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection Treated with Entecavir vs. Tenofovir","volume":"18","author":"Oh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ha, Y., Chon, Y.E., Kim, M.N., Lee, J.H., and Hwang, S.G. (2020). Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-70433-z"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/apt.16116","article-title":"Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-na\u00efve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan","volume":"52","author":"Hu","year":"2020","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_39","first-page":"3882","article-title":"Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan\u2014A retrospective study","volume":"10","author":"Chen","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jvh.13572","article-title":"Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response","volume":"28","author":"Na","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"ref_43","unstructured":"Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2021). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated February 2021), Cochrane. Available online: www.training.cochrane.org\/handbook."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"Schwarzer","year":"2008","journal-title":"Stat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12072-014-9593-x","article-title":"Reimbursement policies in the Asia-Pacific for chronic hepatitis B","volume":"9","author":"Lim","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load","volume":"374","author":"Pan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_49","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: A systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.15867","article-title":"Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B","volume":"52","author":"Oh","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3748\/wjg.v19.i16.2466","article-title":"Hepatocellular carcinoma in patients with chronic kidney disease","volume":"19","author":"Lee","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"647","DOI":"10.7150\/ijms.5904","article-title":"Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients","volume":"10","author":"Miyauchi","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Koyanagi, K., Kubota, T., Kobayashi, D., Kihara, T., Yoshida, T., Miisho, T., Miura, T., Sakamoto, Y., Takaki, J., and Seo, T. (2016). Prescription Factors Associated with Medication Non-adherence in Japan Assessed from Leftover Drugs in the SETSUYAKU-BAG Campaign: Focus on Oral Antidiabetic Drugs. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00212"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chun, H.S., Park, S., Lee, M., Cho, Y., Kim, H.S., Choe, A.R., Kim, H.Y., Yoo, K., and Kim, T.H. (2021). Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Cancers, 13.","DOI":"10.3390\/cancers13143424"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3748\/wjg.v18.i21.2661","article-title":"Family history influences the early onset of hepatocellular carcinoma","volume":"18","author":"Park","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hui, V.W., Yip, T.C., Wong, V.W., Tse, Y.K., Chan, H.L., Lui, G.C., and Wong, G.L. (2021). Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. Clin. Transl. Gastroenterol., 12.","DOI":"10.14309\/ctg.0000000000000324"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.30973","article-title":"Statin Use and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B","volume":"71","author":"Goh","year":"2020","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Marchese, S., Polo, A., Ariano, A., Velotto, S., Costantini, S., and Severino, L. (2018). Aflatoxin B1 and M1: Biological Properties and Their Involvement in Cancer Development. Toxins, 10.","DOI":"10.3390\/toxins10060214"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Leone, P., Solimando, A.G., Fasano, R., Argentiero, A., Malerba, E., Buonavoglia, A., Lupo, L.G., De Re, V., Silvestris, N., and Racanelli, V. (2021). The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 9.","DOI":"10.3390\/vaccines9050532"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Lee, J.I., Kim, S., Kim, S., Chang, H.Y., and Lee, K.S. (2020). Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01236-9"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.cgh.2021.09.001","article-title":"Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B","volume":"20","author":"Jang","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:35Z","timestamp":1760138315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112617"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112617","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}